Supplementary Figure S5 from Human Tumor–Associated Macrophages and Neutrophils Regulate Antitumor Antibody Efficacy through Lethal and Sublethal Trogocytosis

Supplementary Figure S5. (A) Representative dotplots showing the levels of trogocytosis and killing activity mediated by TAM co-cultured with cetuximab-opsonized PKH67+A431 cells at a 50:1 E:T ratio for 12 hrs in the presence of blocking anti-CD32a Ab (clone 2B6) or blocking anti-CD32a Ab (clone 6G11). (B and C) Summary results showing the levels of trogocytosis (B) and killing activity (C) mediated by blood monocytes and TAM co-cultured with cetuximab-opsonized PKH67+A431 cells at a 50:1 E:T ratio for 12 hrs in the presence of blocking anti-CD32a Ab (clone2B6) or anti-CD32a Ab (clone 6G11). Blocking anti-CD32a Ab were added at concentration (10ug/ml). Summary graphs represent the total tumoricidal activity of effectors that was calculated as described in material and methods. IC Ab-isotype control Abs. (D) Representative experiment and cumulative results showing the kinetics of GFP+A431 tumor cell growth with blood monocytes or TAM at a 50:1 E:T ratio in the presence of cetuximab and blocking anti-CD32a Ab (clone2B6) or blocking anti-CD32a Ab (clone 6G11) in the IncuCyte® Live Cell Analysis System. Percentage of tumor cell growth inhibition/stimulation was calculated at 60 hrs as described earlier. Number of patients included in each analysis is indicated on the graphs. One-way ANOVA with Friedman multiple comparisons test. All data represented as mean ± SEM.